BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34049251)

  • 1. High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Sugimoto A; Umemura S; Miyoshi T; Nakai T; Kuroe T; Nosaki K; Ikeda T; Udagawa H; Kirita K; Zenke Y; Matsumoto S; Yoh K; Niho S; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2021 Jul; 157():1-8. PubMed ID: 34049251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
    Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
    Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
    Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differences of biological behavior based on the clinicopathological data between resectable large-cell neuroendocrine carcinoma and small-cell lung carcinoma.
    Kinoshita T; Yoshida J; Ishii G; Aokage K; Hishida T; Nagai K
    Clin Lung Cancer; 2013 Sep; 14(5):535-40. PubMed ID: 23792008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
    Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
    BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.
    Aly RG; Rekhtman N; Li X; Takahashi Y; Eguchi T; Tan KS; Rudin CM; Adusumilli PS; Travis WD
    J Thorac Oncol; 2019 Sep; 14(9):1583-1593. PubMed ID: 31121325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
    Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
    Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
    Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of perioperative chemotherapy for pulmonary high-grade neuroendocrine carcinomas: a propensity score matching analysis.
    Ogawa H; Tanaka Y; Kitamura Y; Shimizu N; Doi T; Hokka D; Tane S; Nishio W; Yoshimura M; Maniwa Y
    J Thorac Dis; 2019 Apr; 11(4):1145-1154. PubMed ID: 31179056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous computed tomography-guided core needle biopsy can be used to histologically confirm the clinical features and long-term prognosis of pulmonary neuroendocrine neoplasms.
    Chen C; Wang Y; Huang H; He X; Li W
    Jpn J Radiol; 2023 Dec; 41(12):1414-1419. PubMed ID: 37395983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
    Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
    Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Grade Neuroendocrine Carcinoma with Bronchial Intraepithelial Tumor Spread: Possibly a New Histologic Feature of Large-Cell Neuroendocrine Carcinoma.
    Kojima H; Watanabe R; Isaka M; Shimizu R; Kayata H; Miyata N; Maniwa T; Takahashi S; Ito I; Kameya T; Funai K; Ohde Y; Nakajima T
    J Thorac Oncol; 2015 Sep; 10(9):1337-1340. PubMed ID: 26291012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
    Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma.
    Minami K; Tanaka Y; Ogawa H; Jimbo N; Nishio W; Yoshimura M; Itoh T; Maniwa Y
    Thorac Cancer; 2019 Nov; 10(11):2152-2160. PubMed ID: 31583856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung.
    Casali C; Stefani A; Rossi G; Migaldi M; Bettelli S; Parise A; Morandi U
    Ann Thorac Surg; 2004 Jan; 77(1):247-52; discussion 252-3. PubMed ID: 14726070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
    Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
    Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
    J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Oshima Y; Haruki T; Matsui S; Makishima K; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2023 Mar; 14(8):758-765. PubMed ID: 36694106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.